<DOC>
	<DOCNO>NCT01513733</DOCNO>
	<brief_summary>The standard care men metastatic CRPC 2010 follow progression docetaxel cabazitaxel abiraterone acetate/prednisone . Based result two study , cabazitaxel prednisone become standard second line chemotherapy regimen become backbone upon improve upon . Thus , primary objective study determine recommend dose tasquinimod combination cabazitaxel prednisone base safety tolerability men chemorefractory metastatic castration-resistant prostate cancer ( CRPC ) .</brief_summary>
	<brief_title>The CATCH Prostate Cancer Trial : Cabazitaxel And Tasquinimod Men With Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>1 . Histologically cytologically confirm adenocarcinoma prostate without small cell feature ; 2 . At least 18 year age signing Informed Consent ; 3 . Presence metastatic disease bone scan CT/MRI imaging ; 4 . Ongoing androgen deprivation therapy gonadotropin release hormone ( GnRH ) analogue orchiectomy ( i.e. , medical surgical castration ) ; 5 . For patient orchiectomy , must plan maintain effective GnRHanalogue therapy duration trial ; 6 . Serum testosterone level &lt; 50 ng/dL Screening Visit ; 7 . Progressive disease follow docetaxelbased chemotherapy medical surgical castration . Patients intolerant docetaxel also allow . Disease progression study entry define one follow three criterion : 1 ) PSA progression define minimum three rise PSA level interval ≥ 1 week determination . The PSA value Screening visit ≥ 2 μg/L ( 2 ng/mL ) ; 2 ) Soft tissue disease progression define RECIST 1.1 ; 3 ) Bone metastatic disease progression define one new lesion bone scan clinically consistent tumor flare ; 8 . No three prior chemotherapy regimen least one regimen contain docetaxel ( unless intolerant per # 7 ) ; 9 . Karnofsky Performance Status &gt; 70 ; 10 . Estimated life expectancy least three month ; 11 . Able swallow study drug comply study requirement ; 12 . Willing able give inform consent . 1 . Subjects &gt; 80 year old ( dose escalation phase , due low clearance elderly patient ) ; 2 . Severe concurrent disease , infection , comorbidity , judgment investigator , would make patient inappropriate enrollment ; 3 . Metastases brain active epidural disease ( NOTE : patient treat epidural disease allow provide follow imaging document stability epidural disease ) ; 4 . Absolute neutrophil count &lt; 1,200/μL , platelet count &lt; 100,000/μL , hemoglobin &lt; 9 g/dL Screening Visit ; ( NOTE : patient may receive growth factor blood transfusion within seven day hematologic laboratory value obtain Screening Visit ) 5 . Total bilirubin , alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) &gt; 1.5 time upper limit normal Screening Visit ; 6 . Creatinine &gt; 1.5 x ULN Screening visit ; 7 . History another malignancy within previous 3 year nonmelanomatous skin cancer noninvasive bladder cancer treat curative intent ; 8 . Treatment androgen receptor antagonist ( bicalutamide , flutamide , nilutamide , MDV3100 ) , 5α reductase inhibitor ( finasteride , dutasteride ) , estrogens ( ie DES ) , sipuleucelT , chemotherapy within 28 day Day 1 visit plan initiate treatment treatment study ; 9 . Use herbal product may decrease PSA level systemic corticosteroid great equivalent 10 mg prednisone/prednisolone per day within four week Day 1 visit ; 10 . Ongoing treatment warfarin unless international normalize ratio ( INR ) well control 4 11 . Exposure ketoconazole strong CYP3A4 inhibitor inducer intravenously orally within 28 day prior Day 1 Visit . For abiraterone acetate TAK700 , 14 day washout need . 12 . Ongoing treatment sensitive CYP1A2 substrates CYP1A2 substrate narrow therapeutic range ( Appendix 3 ) . 13 . Ongoing treatment CYP3A4 substrates narrow therapeutic range ( Appendix 3 ) . 14 . Radiation therapy within 2 week ( single fraction radiotherapy within 2 week ) radionuclide therapy within 8 week Day 1 visit ; 15 . Planned palliative procedure alleviation bone pain radiation therapy surgery ; 16 . Structurally unstable bone lesion suggest impending fracture ; 17 . Clinically significant cardiovascular disease include : myocardial infarction within 6 month , uncontrolled angina within 3 month , congestive heart failure , Diagnosed suspect congenital long QT syndrome ; significant ventricular arrhythmia , Prolonged correct QT interval Fridericia Bazett correction formula , History Mobitz II second degree third degree heart block without permanent pacemaker place ; Hypotension ( systolic blood pressure &lt; 86 mMHg bradycardia heart rate &lt; 50 beat per minute ECG take Screening Day 1 visit ; Uncontrolled hypertension ; TIA stroke/CVA within 6 month Day 1 visit ; Rest limb claudication ischemia within 6 month Day 1 visit 18 . Use investigational agent within four week Day 1 visit plan initiate treatment investigational agent study ; 19 . Gastrointestinal disorder affect absorption ( e.g. , gastrectomy , active peptic ulcer disease within last three month ) ; 20 . Major surgery within four week prior Day 1 visit . 21 . Presence NCI CTC grade &gt; 1 peripheral neuropathy 22 . History pancreatitis 23 . Known positive serology HIV ( patient know history HIV exclude potential unforeseen toxicity morbidity immunocompromised host ) . 24 . Chronic hepatitis B C advance , decompensated hepatic disease , cirrhosis liver history chronic viral hepatitis know viral hepatitis carrier ( patient recover hepatitis allow enter study ) . 25 . Documented prior disease progression tasquinimod</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>